EGFR and non-small cell lung carcinoma: The FDA recently approved two IVD (in vitro diagnosis) tests (Cobas EGFR Mutation Test v2, Roche, and Idylla TM ctEGFR Mutation Assay) for NSCLC patients, which employs plasma samples for the detection of EGFR resistance mutation p.(Tyr790Met), exon 19 deletions and p/L858R mutations [61].